NEWS: Leidos' Eric Stahlberg Named to FCW's 2017 Federal 100

March 31, 2017 Media Relations

RESTON, Va.March 31, 2017 /PRNewswire/ -- Leidos (NYSE: LDOS), a global science and technology company, today announced that Eric Stahlberg, director of high-performance computing at the subsidiary Leidos Biomedical Research, Inc., was honored on FCW's Federal 100 list for his work on advancing cancer research. The Fed 100 list recognizes leaders in the information technology (IT) community who had the greatest impact in 2016. The winners were chosen on the merits of their work advancing government agency missions through IT.

Stahlberg has been instrumental in efforts to connect the National Cancer Institute (NCI) and the Department of Energy (DOE) and thereby extend the use of high-performance computing in cancer research. He has been a key force driving predictive oncology at the Frederick National Laboratory for Cancer Research (FNLCR), which is operated by Leidos Biomedical Research and sponsored by NCI.

The FCW award cited Stahlberg's contribution to establishing the three pilot projects of the Joint Design of Advanced Computing Systems for Cancer (JDACS4C) to advance predictive oncology, securing a signed memorandum of understanding from NCI and the DOE to work together, and engaging the extramural community in a national "Frontiers of Predictive Oncology" meeting to help move the field forward.

"Employees like Eric embody the Leidos spirit of drive, ingenuity and dedication," said David Heimbrook, Ph.D., president Leidos Biomedical Research. "We are honored to have an employee of this caliber recognized for his important contributions to our mission."

About Leidos

Leidos is a global science and technology solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil and health markets. The company's 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, VirginiaLeidos reported annual revenues of approximately $7.04 billion for the fiscal year ended December 30, 2016. For more information, visit

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended December 30, 2016, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.


Media Contacts:

Melissa Koskovich, SVP Communications, (571) 526-6850,

Jason Kello, Director - Media Relations,

More Content by Media Relations
Previous Article
Four Go-Live Best practices to Successfully Complete an EHR Launch
Four Go-Live Best practices to Successfully Complete an EHR Launch

After months of preparation, the real test of your electronic health records (EHR) system is when your prov...

Next Article
Leidos Biomed Supports Phase II Clinical Trial for Chikungunya Vaccine
Leidos Biomed Supports Phase II Clinical Trial for Chikungunya Vaccine

An experimental vaccine for mosquito-borne chikungunya is being tested as part of a Phase II vaccine clinic...